Search
Research
Exploiting temporal aspects of cancer immunotherapyMany mechanisms underlying an effective immunotherapy-induced antitumour response are transient and critically time dependent. This is equally true for several immunological events in the tumour microenvironment induced by other cancer treatments. Immune checkpoint therapy (ICT) has proven to be very effective in the treatment of some cancers, but unfortunately, with many cancer types, most patients do not experience a benefit.
Research
Sensitizing the Tumor Microenvironment to Immune Checkpoint TherapyIn this review we explore the current literature about the predictive characteristics of the tumor microenvironment and discuss therapeutic approaches
Research
Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemiaThe aim of our study was to investigate whether CBL0137 has potential as a therapeutic and chemopotentiating compound in MLL-r leukemia
Research
Challenges to curing primary brain tumoursThe seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment in brain tumours
Research
Bilateral murine tumor models for characterizing the response to immune checkpoint blockadeThis protocol describes bilateral murine tumor models that display a symmetrical yet dichotomous response to immune checkpoint blockade
Research
Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003-2013Invasive fungal infections are more common in children with high-risk acute lymphoblastic leukaemia and in relapsed disease
Research
Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: Findings from the Childhood Leukaemia International ConsortiumWe did not find any associations between parental occupational extremely low-frequency magnetic fields exposure and childhood leukaemia
Research
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaOur study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia
Research
The Australian and New Zealand Children's Haematology/Oncology Group Biobanking NetworkThe ANZCHOG-BN was developed to improve and streamline access to high quality pediatric and adolescent/young adult cancer biospecimens for cancer research
Research
Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG RegistryThese findings provide a compelling argument for efforts to reduce exposure of the brainstem in the treatment of medulloblastoma